Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IOVA - Iovance Biotherapeutics Inc


IEX Last Trade
11.65
0.270   2.318%

Share volume: 3,960,271
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$11.38
0.27
2.37%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 25%
Dept financing 2%
Liquidity 49%
Performance 17%
Company vs Stock growth
vs
Performance
5 Days
-1.77%
1 Month
30.13%
3 Months
29.56%
6 Months
-33.10%
1 Year
89.29%
2 Year
11.58%
Key data
Stock price
$11.65
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$3.21 - $18.33
52 WEEK CHANGE
$0.90
MARKET CAP 
3.263 B
YIELD 
N/A
SHARES OUTSTANDING 
279.833 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,554,758
AVERAGE 30 VOLUME 
$7,451,713
Company detail
CEO:
Region: US
Website: iovance.com
Employees: 480
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical

Recent news